TABLE 7.

Simulated steady-state area under the curve from time zero to 12 h ( ${\mathrm{A}\mathrm{U}\mathrm{C}}_{0\to 12h})$ and the corresponding average $C_{ss}$ ( ${\overline{C}}_{ss}$ ) values of VPA under the dosage regimen of 500 mg/bid in terms of four different scenarios based on the XGBoost model.

Scenarios	${\mathrm{A}\mathrm{U}\mathrm{C}}_{0\to 12h}$ (mg·h/L)	${\overline{C}}_{ss}$ (mg/L)
Scenario 1	1,093.3 ± 170.2	91.1 ± 14.2
Scenario 2	683.4 ± 103.7	56.9 ± 8.6
Scenario 3	1,187.5 ± 183.5	99.0 ± 15.3
Scenario 4	765.4 ± 117.0	63.8 ± 9.8

Note: Scenario 1 denotes patients with CYP2C19*2 and/or *3 variants and taking co-administered CBZ + PHT + PB), Scenario 2 denotes patients with CYP2C19*1*1 genotype and taking co-administered CBZ + PHT + PB, Scenario 3 denotes patients with CYP2C19*2 and/or *3 variants and NOT taking co-administered CBZ, PHT, or PB, and Scenario 4 denotes patients with CYP2C19*1*1 genotype and NOT taking co-administered CBZ, PHT, or PB.